AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04495751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muscadine grape extract
Description: Four pills twice daily
Study NCT04495751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four pills twice daily.
Study NCT04364256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Description: Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Ancillary studies
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Ancillary studies
Study NCT04364256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Description: Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant Feedback
Description: Ancillary studies
Study NCT04495751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Participant Feedback
Description: Ancillary studies
Study NCT05295433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-3705
Description: A sterile liquid for injection
Study NCT06293911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair Plus Parodontgel Intensive
Description: The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
Study NCT06293911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
Study NCT06633016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-002
Description: ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Study NCT06633016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Study NCT06737315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
Study NCT06737315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
Study NCT06738069 — intervention group
Intervention type: OTHER
Intervention: Participants are not assigned an intervention as a part of the study
Description: Participants are not assigned an intervention as a part of the study
Study NCT06740045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: 10 patients will receive teszpire
Study NCT06741098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCR100
Description: Subjects will receive multiple intra-articular NCR100 injections.
Study NCT06741098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: Subjects will receive multiple intra-articular 0.9% Normal saline injections.
Study NCT06741098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% Normal saline
Description: Subjects will receive multiple intra-articular 0.9% Normal saline injections.
Study NCT06738160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalusobasumab
Description: Patients with advanced bone metastases who have not received any prior systemic therapy for non-small cell lung cancer will receive first-line treatment with nalusolimab and bone target lesion SBRT plus conventional dose immune checkpoint inhibitors and chemotherapy, including nalproxolimab 120 mg/time, subcutaneous injection, administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24 Gy/3 F is used for spinal metastases, and 30 Gy/5 F or 35 Gy/5 F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines until progression.
Study NCT06741358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glialia
Description: Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.
Study NCT06741358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.
Study NCT06741358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
Study NCT06740136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle induced-damage eccentric exercise
Study NCT06738992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
Study NCT06738992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
Study NCT06736704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV4818
Description: SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Study NCT05689060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulling Straight leg raising technique
Description: Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
Study NCT05689060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post facilitation stretch
Description: Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
Study NCT05139030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome injectable suspension
Description: Adductor canal block with EXPAREL
Study NCT06278844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.
Study NCT06278844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular apical pacing
Description: This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
Study NCT04547920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Bladder Modulation System-1x per week
Description: Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation
Study NCT04547920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Bladder Modulation System - 3x per week
Description: Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation
Study NCT05503069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions with social and cultural components
Description: Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study.
Study NCT04647890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT011
Description: Two x 100mg capsules once daily for 12 weeks
Study NCT04647890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT011
Description: Two x 200mg capsules once daily for 12 weeks
Study NCT04647890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules once daily for 12 weeks
Study NCT06246279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation to Adolescence and Type 1 Diabetes Management Training Program
Description: The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
Study NCT04519177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Education Program (SHEP)
Description: Sleep Health Education Program (SHEP) including screening for common sleep disorders
Study NCT04604691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab for Injection
Description: Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
Study NCT06458075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CO-LEAD
Description: The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
Study NCT04879979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT
Description: MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
Study NCT06080139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refugee parenting education in a participatory community
Description: Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas.
Study NCT06080139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Refugee parenting education in a participatory community
Description: Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas.
Study NCT05088655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
Study NCT05139030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Adductor Canal Block with bupivacaine HCl
Study NCT06736704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
Study NCT05278091 — intervention group
Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study
Study NCT05694585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
Study NCT05694585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
Study NCT05031221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga + behavioral weight loss
Description: A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
Study NCT05009082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
Study NCT05009082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
Study NCT05009082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year
Study NCT05009082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: 200 or 300 mg capsules once daily for up to a total of 3 years
Study NCT04913298 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosorb therapy
Description: Start of Cytosorb therapy is at the discretion of the attending physician
Study NCT06739564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE PACKING
Description: ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.
Study NCT06739564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRY NEEDLING
Description: DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
Study NCT06475378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moonbird
Description: Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
Study NCT06475378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
Study NCT06475378 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
Study NCT06475378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
Study NCT06370975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% hypertonic Saline
Description: the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100